STAT3 activation by Paclitaxel, via the induction of reactive oxygen species, has been demonstrated in several tumor types [51]; however, this phenomenon is cell-type-specific, and conflicting effects on STAT3 expression in response to Paclitaxel have been reported in ovarian cancers [52,53,54]. This evidence concerns the gene STAT3 and neoplasm.